Company intelligence / Profile preview

Perftoran West Ltd

United Kingdom

Ownership: Private
Development stage: Other

Overview

Perftoran, the company's artificial blood product (perfluorocarbon emulsion), was approved in Russia (1996), Ukraine, Kazakhstan, Mexico (2005-2010 as Perftec), and administered to over 40,000 patients with good success and few adverse reactions. Rebranded as Vidaphor for North America.

Therapeutic areas: HematologyCardiovascularNeurologyInfectious DiseasesOncology
Modalities: Perfluorocarbon emulsion
Industry: Biotech

Beyond the preview

Go deeper on Perftoran West Ltd.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perftoran West Ltd.

Explore the full profile